GSK plc (LSE/NYSE: GSK) will share latest research findings from across its diverse respiratory portfolio of innovative therapies, including targeted biologics, vaccines and inhaled medicines, at the 2024 European Respiratory Society (ERS) International Congress in Vienna (7-11 September). The research, including three late-breaking abstracts, demonstrates the company’s commitment and ongoing ambition to redefine the future of respiratory medicine and deliver the next generation standard of care for millions of people affected by respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), refractory chronic cough and respiratory syncytial virus (RSV)..

葛兰素史克股份有限公司（伦敦证交所/纽约证交所：葛兰素史克）将在维也纳举行的2024年欧洲呼吸学会（ERS）国际大会（9月7日至11日）上分享其多种呼吸创新疗法的最新研究结果，包括靶向生物制剂、疫苗和吸入药物。这项研究，包括三篇最新的摘要，展示了该公司的承诺和持续的雄心，即重新定义呼吸医学的未来，并为数百万受哮喘、慢性阻塞性肺病（COPD）、难治性慢性咳嗽和呼吸道合胞病毒（RSV）等呼吸系统疾病影响的人提供下一代护理标准。。

GSK’s ambitious goals build on decades of expertise, research and collaboration as the company works to reduce the global burden of respiratory diseases by providing protection from infections and the associated complications, preventing exacerbations, cumulative lung damage and disease progression while providing optimal treatment of symptoms.

葛兰素史克的雄心勃勃的目标建立在数十年的专业知识、研究和合作基础上，该公司致力于通过提供感染和相关并发症的保护，防止恶化、累积肺损伤和疾病进展，同时提供最佳的症状治疗，减轻全球呼吸系统疾病的负担。

This means aiming for clinical remission for as many people with asthma as possible at the earliest point in their disease journey to protect their future health..

这意味着尽可能多的哮喘患者在疾病旅程的最早阶段就获得临床缓解，以保护他们未来的健康。。

Study results from SWIFT-1 and SWIFT-2

SWIFT-1和SWIFT-2的研究结果

The first presentation of the positive results from SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterised by blood eosinophil count, will be shared in a late-breaking alert session on Monday, 9 September at 3.45 CEST.

SWIFT-1和SWIFT-2的首次阳性结果评估了依莫单抗与安慰剂在成人和青少年严重哮喘患者中的疗效和安全性，以血液嗜酸性粒细胞计数为特征的2型炎症为特征，将在9月9日星期一3:45 CEST的晚期警报会议上分享。

Depemokimab is the first ultra-long-acting biologic to be evaluated in phase III trials with a binding affinity and high potency for interleukin-5 (IL-5), enabling six-month dosing intervals for patients with severe asthma. Long-acting treatments that combine an extended half-life with high potency have the potential to offer sustained suppression of the underlying drivers that contribute to disease outcomes and progression for extended periods..

Depemokimab是第一个在III期试验中评估的超长效生物制剂，对白细胞介素-5（IL-5）具有结合亲和力和高效力，为严重哮喘患者提供了六个月的给药间隔。结合延长半衰期和高效能的长效治疗有可能持续抑制导致疾病结果和长期进展的潜在驱动因素。。

Clinical remission in severe asthma

重症哮喘的临床缓解

Data presented at ERS for Nucala (mepolizumab) builds on the already robust and expansive data on the role of targeting IL-5. Aiming for clinical remission is a critical treatment goal for patients with severe asthma and type 2 inflammation. Further data on clinical remission provides additional insights into evidence-based management strategies with research looking at characteristics that influence clinical remission and also the role of biologic therapy in achieving this treatment goal.

ERS为Nucala（mepolizumab）提供的数据建立在关于靶向IL-5作用的已经强大且广泛的数据基础上。。有关临床缓解的进一步数据为循证管理策略提供了更多见解，研究着眼于影响临床缓解的特征以及生物治疗在实现这一治疗目标中的作用。

Additional research for Trelegy (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) will also look at clinical remission as a treatment goal in in other types and severities of asthma..

Trelegy（糠酸氟替卡松/umeclidinium/维兰特罗或FF/UMEC/VI）的其他研究也将临床缓解视为其他类型和严重程度哮喘的治疗目标。。

Research on COPD exacerbations

慢性阻塞性肺疾病急性加重的研究进展

A post-hoc analysis from METREX and METREO will be presented, which shows the effect of Nucala in the trial participants with or without chronic bronchitis. A poster presentation of the study design of MATINEE, the third clinical study of Nucala in COPD, will be presented. MATINEE recruited COPD patients with broad clinical presentations of chronic bronchitis and/or emphysema, along with evidence of type 2 inflammation characterised by blood eosinophil count and builds on existing data for Nucala.

将介绍METREX和METREO的事后分析，显示Nucala在有或没有慢性支气管炎的试验参与者中的作用。将展示日场研究设计的海报，这是努卡拉在COPD中的第三项临床研究。日场招募的COPD患者具有广泛的慢性支气管炎和/或肺气肿的临床表现，以及以血液嗜酸性粒细胞计数为特征的2型炎症的证据，并基于Nucala的现有数据。

Research being presented at ERS also includes the latest evidence to support the use of Trelegy in COPD and more specifically advancing research of disease stability as a realistic treatment goal..

ERS正在进行的研究还包括支持在COPD中使用Trelegy的最新证据，更具体地说，将疾病稳定性研究作为现实的治疗目标。。

Key abstracts presented at ERS

ERS上发表的关键摘要

Encouraging new data will be presented from GSK’s portfolio that could transform outcomes for patients living with respiratory disease.

GSK的投资组合将提供令人鼓舞的新数据，这些数据可能会改变呼吸系统疾病患者的预后。

Abstract Name

摘要名称

Presenter

演示者

Presentation Details

演示文稿详细信息

Depemokimab efficacy/safety in patients with asthma on medium/high-dose ICS: the Phase IIIA randomised SWIFT-1/2 studies

Depemokimab对中/高剂量ICS哮喘患者的疗效/安全性：IIIA期随机SWIFT-1/2研究

D. Jackson

D、 杰克逊

Oral presentation Session 356#RCT3718

口头报告会议356#RCT3718

Depemokimab PK/PD in the 52-week randomised double-blind multicentre Phase III SWIFT-1 trial

Depemokimab PK/PD在52周随机双盲多中心III期SWIFT-1试验中的应用

I. Pavord

I.帕沃德

Oral presentation Session 345 #OA3647

口头报告会议345#OA3647

Mepolizumab in patients with asthma and features of COPD: a MENSA/MUSCA post hoc analysis

美妥珠单抗在哮喘和慢性阻塞性肺病患者中的应用：MENSA/MUSCA 事后分析

I. Pavord

I.帕沃德

Poster presentation Session 415 #PA4492

海报展示环节415#PA4492

Mepolizumab response in patients with COPD and an eosinophilic phenotype with/without chronic bronchitis (CB): a METREX/METREO post hoc analysis

慢性阻塞性肺疾病和嗜酸性粒细胞表型伴/不伴慢性支气管炎（CB）患者的Mepolizumab反应：METREX/METREO事后分析

C. Vogelmeier

C.沃格尔梅尔

Poster presentation Session 460 #PA4783

海报展示环节460#PA4783

Clinical trial design of biologic therapies in COPD: MATINEE study of mepolizumab

慢性阻塞性肺病生物疗法的临床试验设计：甲波利珠单抗的 MATINEE 研究

I. Pavord

I.帕沃德

Poster presentationSession 460 #PA4789

海报展示会话460#PA4789

Real-world assessment of clinical remission in asthma with biologics

生物制剂对哮喘临床缓解的现实评估

P. Howarth

P、 霍沃斯

Poster presentation Session 225#PA2182

海报展示课程225#PA2182

Clinical characteristics impacting clinical remission attainment in REALITI-A

影响REALITI-A临床缓解程度的临床特征

Poster presentation Session 133#PA1200

海报展示会133#PA1200

Assessment of the components of clinical remission with moderate–severe asthma after 24–52 weeks of treatment: CAPTAIN post hoc analysis

治疗24-52周后评估中重度哮喘临床缓解的组成部分：CAPTAIN事后分析

I. Pavord

I.帕沃德

Poster presentation Session 133#PA1198

海报展示会133#PA1198

Characteristics of patients meeting the components of clinical remission: CAPTAIN post hoc analysis

符合临床缓解成分的患者特征：CAPTAIN事后分析

S. Noorduyn

美国东北部

Poster presentation Session 133#PA1197

海报展示会133#PA1197

Impact of varying lung function threshold on clinical remission in asthma with FF/UMEC/VI: CAPTAIN post hoc analysis

不同肺功能阈值对FF/UMEC/VI哮喘临床缓解的影响：CAPTAIN事后分析

I. Pavord

I.帕沃德

Poster presentation Session 133#PA1199

海报展示会133#PA1199

Towards disease stability in COPD management: patient perspectives

COPD管理中的疾病稳定性：患者观点

M. Brooke

M、 布鲁克

Poster presentationSession 132#PA1171

海报展示会132#PA1171

Impact of varying health status thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis

FF/UMEC/VI不同健康状况阈值对COPD疾病稳定性的影响：影响事后分析

D. Halpin

D、 哈尔平

Poster presentationSession 132#PA1173

海报展示会132#PA1173

Impact of varying lung function thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis

不同肺功能阈值对FF/UMEC/VI COPD疾病稳定性的影响：影响事后分析

D. Halpin

D、 哈尔平

Oral presentation Session 443#OA4653

口头报告会议443#OA4653

About GSK in respiratory

关于呼吸系统中的GSK

GSK continues to build on decades of pioneering work to deliver more ambitious treatment goals, develop the next generation standard of care, and redefine the future of respiratory medicine for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics and inhaled medicines, we are focused on improving outcomes and the lives of people living with all types of asthma and COPD along with less understood refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease.

凭借业界领先的呼吸产品组合和疫苗、靶向生物制剂和吸入药物管道，我们专注于改善患有各种类型哮喘和COPD以及不太了解的难治性慢性咳嗽或罕见疾病（如系统性硬化症伴间质性肺病）的患者的预后和生活。

GSK is harnessing the latest science and technology with the aim to modify underlying disease dysfunction and prevent disease progression..

葛兰素史克利用最新的科学技术，旨在改变潜在的疾病功能障碍，预防疾病进展。。

About GSK

GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

葛兰素史克是一家全球性生物制药公司，旨在将科学、技术和人才团结起来，共同战胜疾病。更多信息请访问gsk.com。